Carbapenems and subsequent multiresistant bloodstream infection: does treatment duration matter?

International Journal of Antimicrobial Agents

Volumn 34, Issue 3, 2009, Pages 246-251

  Donaldson, Annabelle D ^a,b   Razak, Lubna ^b   Liang, Li Jia ^c   Fisher, Dale A ^a,b   Tambyah, Paul A ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antimicrobial resistance; Carbapenem; Intensive care; Nosocomial infection

Indexed keywords

CARBAPENEM;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; DRUG RESPONSE; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CARBAPENEMS; CRITICAL ILLNESS; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 67650751325     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.04.007     Document Type: Article

References (38)

1. Kruger B.E., Craven D.E., and McCabe W.R. Gram-negative bacteremia IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68 (1980) 344-355
2. Kollef M.H., Sherman G., Ward S., and Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
3. Luna C.M., Vujacich P., Niederman M.S., Vay C., Gherardi C., Matera J., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111 (1997) 676-685
4. Iregui M., Ward S., Sherman G., Fraser V.J., and Kollef M.H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122 (2002) 262-268
5. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., and Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
6. Niederman M.S. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 42 Suppl. 2 (2006) S72-81
7. Höffken G., and Niederman M.S. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 122 (2002) 2183-2196
8. Tambyah P.A., Habib A.G., Poh C.L., Kumarasinghe G., and Chow C. Clinical and molecular epidemiology of invasive Klebsiella pneumoniae infections in the extended-spectrum β-lactamase (ESBL) era. Med J Malaysia 56 Suppl. B (2001) 19
9. Rahal J.J., Urban C., and Segal-Maurer S. Nosocomial antibiotic resistance in multiple Gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis 34 (2002) 499-503
10. Carmeli Y., Troillet N., Eliopoulos G.M., and Samore M.H. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43 (1999) 1379-1382
11. Lepper P.M., Grusa E., Reichl H., Högel J., and Trautmann M. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 46 (2002) 2920-2925
12. Lee S.O., Kim N.J., Choi S.H., Tae H.K., Chung J.W., Woo J.H., et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 48 (2004) 224-228
13. del Mar Thomas M., Cartelle M., Pertega S., Beceiro A., Llinares P., Canle D., et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 11 (2005) 540-546
14. Morimoto Y., Sugiura T., Tatebayashi S., and Kirita T. Reduction in incidence of methicillin-resistant Staphylococcus aureus (MRSA) after radical surgery for head and neck cancer. Spec Care Dentist 26 (2006) 209-213
15. Hsueh P.H., Chen W.H., Teng L.J., and Luh K.T. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 26 (2005) 43-49
16. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement. Document M100-S15. Wayne, PA: CLSI; 2005.
17. Ministry of Health, Singapore. Clinical practice guidelines. Use of antibiotics in adults (2006), Integrated Press Pte Ltd, Singapore
18. Fridkin S.K., Steward C.D., Edwards J.R., Pryor E.R., McGowan Jr. J.E., Archibald L.K., et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2 Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 29 (1999) 245-252
19. WHO Collaborating Centre for Drug Statistics Methodology. The ATC/DDD system. http://www.whocc.no/atcddd [accessed 30.11.08].
20. Safdar N., and Maki D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 136 (2002) 834-844
21. D'Agata E.M., Venkataraman L., DeGirolami P., Burke P., Eliopoulos G.M., Karchmer A.W., et al. Colonization with broad-spectrum cephalosporin-resistant Gram-negative bacilli in intensive care units during a nonoutbreak period: prevalence, risk factors, and rate of infection. Crit Care Med 27 (1999) 1090-1095
22. Guillemot D., Carbon C., Balkau B., Geslin P., Lecoeur H., Vauzelle-Kervroëdan F., et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. J Am Med Assoc 279 (1998) 365-370
23. Ruhe J.J., and Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 36 (2003) 1132-1138
24. Singh N., Rogers P., Atwood C.W., Wagener M.M., and Yu V.L. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162 (2000) 505-511
25. Chastre J., Wolff M., Fagon J.Y., Chevret S., Thomas F., Wermert D., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. J Am Med Assoc 290 (2003) 2588-2598
26. Nseir S., Pompeo C.D., Soubrier S., Delour P., Lenci H., Roussel-Delvallez M., et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit. Crit Care Med 33 (2005) 283-289
27. Davey P., Brown E., Fenelon L., Finch R., Gould I., Holmes A., et al. A systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis 12 (2006) 211-216
28. Verhoef J., Beaujean D., Blok H., Baars A., Meyler A., van der Werken, et al. A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 18 (1999) 461-466
29. Grundmann H., Bärwolff S., Tami A., Behnke M., Schwab F., Geffers C., et al. How many infections are caused by patient-to-patient transmission in intensive care units?. Crit Care Med 33 (2005) 946-951
30. Chetchotisakd P., Phelps C.L., and Hartstein A.I. Assessment of bacterial cross-transmission as a cause of infections in patients in intensive care units. Clin Infect Dis 18 (1994) 929-937
31. Weist K., Pollege K., Schulz I., Rüden H., and Gastmeier P. How many nosocomial infections are associated with cross-transmission? A prospective cohort study in a surgical intensive care unit. Infect Control Hosp Epidemiol 23 (2002) 127-132
32. Bertrand X., Blasco G., Belle E., Boillot A., Capellier G., and Talon D. Pseudomonas aeruginosa epidemiology in intensive care units: importance of cross-transmission. Ann Fr Anesth Reanim 22 (2003) 505-509 [in French]
33. Scarsi K.K., Feinglass J.M., Scheetz M.H., Postelnick M.J., Bolon M.K., and Noskin G.A. Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay. Antimicrob Agents Chemother 50 (2006) 3555-3560
34. Turnidge J. Impact of antibiotic resistance on the treatment of sepsis. Scand J Infect Dis 35 (2003) 677-682
35. Zaragoza R., Artero A., Camarena J.J., Sancho S., González R., and Nogueira J.M. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 9 (2003) 412-418
36. Fang C.T., Shau W., Hsueh P.R., Chen Y.C., Wang J.T., Hung C.C., et al. Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on outcome. J Antimicrob Chemother 57 (2006) 511-519
37. Yu V.L., Chiou C.C., Feldman C., Ortqvist A., Rello J., Morris A.J., et al. International Pneumococcal Study Group. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37 (2003) 230-237
38. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416